Want to see SG:1H3 full AI Analyst Report?
Top Page
Clearbridge Health Ltd.
(SGX:1H3)
Select Model
Select Model
Rating:43Neutral
Price Target:
S$0.01
▲(0.00% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily weighed down by weak financial performance: ongoing losses, a material loss widening in 2025, and multi-year negative operating/free cash flow. Valuation is also constrained by a negative P/E and no stated dividend yield. Technicals contribute neutrally because key indicators were not provided.
Positive Factors
Diversified service revenue streams
Clearbridge operates multiple complementary revenue lines—individual screening packages, per-test diagnostics, and employer wellness contracts. This diversified service mix supports recurring contract revenue, cross-sell of follow-up services, and resilience to demand swings across segments over the medium term.
Negative Factors
Structural unprofitability
The company has reported multi-year net losses with a material widening in 2025, indicating costs materially exceed gross profit. Persistent operating losses undermine retained earnings and make it harder to achieve sustainable profitability without significant cost restructuring or revenue scale-up.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified service revenue streams
Clearbridge operates multiple complementary revenue lines—individual screening packages, per-test diagnostics, and employer wellness contracts. This diversified service mix supports recurring contract revenue, cross-sell of follow-up services, and resilience to demand swings across segments over the medium term.
Read all positive factors
Clearbridge Health Ltd. (1H3) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$6.44M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.29
Revenue GrowthN/A
EPS GrowthN/A
CountrySG
Employees113
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding6,443,731,400
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.91
Price to Sales (P/S)0.66
P/FCF Ratio-2.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Clearbridge Health Ltd. Business Overview & Revenue Model
Company Description
Established in 2010 and headquartered in Singapore, Clearbridge Health Limited operates as an investment holding company, delivering diverse healthcare solutions globally, including in Singapore, the Philippines, Hong Kong, and Malaysia. The firm'...
How the Company Makes Money
Clearbridge Health Ltd. generates revenue primarily by charging fees for healthcare services delivered to individuals and corporate clients. Key revenue streams include (i) health screening and medical check-up packages (often sold as bundled prog...
Clearbridge Health Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.99M | 9.93M | 9.90M | 10.41M | 16.41M | 11.44M |
| Gross Profit | 2.37M | 5.06M | 4.78M | 5.13M | 9.58M | 6.36M |
| EBITDA | -11.39M | -11.61M | -2.06M | -32.17M | -7.63M | -7.65M |
| Net Income | -11.93M | -12.91M | -3.61M | -32.20M | -11.14M | -19.97M |
Balance Sheet | ||||||
| Total Assets | 9.99M | 9.84M | 21.22M | 23.92M | 58.18M | 82.72M |
| Cash, Cash Equivalents and Short-Term Investments | 4.12M | 990.00K | 3.17M | 4.48M | 6.05M | 14.55M |
| Total Debt | 703.00K | 1.46M | 6.24M | 7.64M | 7.47M | 12.74M |
| Total Liabilities | 3.26M | 4.60M | 10.17M | 10.64M | 12.51M | 25.41M |
| Stockholders Equity | 6.59M | 3.45M | 9.21M | 10.19M | 42.32M | 52.21M |
Cash Flow | ||||||
| Free Cash Flow | -1.56M | -2.71M | -2.10M | -4.12M | -2.67M | -3.83M |
| Operating Cash Flow | -1.53M | -2.66M | -1.93M | -3.57M | -1.98M | -2.99M |
| Investing Cash Flow | -131.00K | -57.00K | 1.18M | 3.07M | -1.08M | 1.18M |
| Financing Cash Flow | 4.81M | 541.00K | 266.00K | -1.88M | -2.56M | 2.46M |
Clearbridge Health Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
SG:1H3
Clearbridge Health Ltd.
―
―
―
SG:505
Asiamedic Limited
0.02
<0.01
6.25%
SG:584
AJJ Medtech Holdings Limited
0.01
0.00
0.00%
SG:MIJ
Alliance Healthcare Group Ltd.
0.19
0.06
44.96%
SG:OTX
Medinex Ltd.
0.23
0.03
14.43%
SG:V8Y
Quantum Healthcare Ltd.
―
―
―
Clearbridge Health Ltd. Corporate Events
Clearbridge Health reshapes board and audit, remuneration committees
Aug 3, 2026
Clearbridge Health Limited has overhauled its board and committee structure with effect from 3 August 2026, following the cessation of Lead Independent Director Andrew John Lord and Independent Director Mark Benedict Ryan, who also stepped down fr...
Clearbridge Health reshapes board and committees with new chairman
Jul 1, 2026
Clearbridge Health has overhauled its board structure with the appointment of Wu Yu Liang as non-executive and independent chairman and Vitters Sim Yu Xiong as a non-executive, non-independent director, effective 1 July 2026. The moves expand the ...
Clearbridge Health AGM Approves Board Changes, Share Mandates and 2025 Accounts
May 6, 2026
Clearbridge Health Limited held its annual general meeting on 23 April 2026 in Singapore, where shareholders adopted the audited financial statements for the year ended 31 December 2025 and approved directors’ fees of up to S$120,000 for the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.